VCYT

VeracyteD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$46.76

Analysis reference price unavailable

Analysis 2025-10-29 · RankAlpha Sentiment AI

Most likely

Base case

60%

Probability

Target price

$39.57

Analysis reference price unavailable

Analysis 2025-10-29 · RankAlpha Sentiment AI

B-

Bear case

20%

Probability

Target price

$28.78

Analysis reference price unavailable

Analysis 2025-10-29 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2025-10-29

AI commentary

Market tone around Veracyte is cautiously constructive: recent trade levels sit modestly above the latest official close, indicating some investor support [#PRICE-2025-10-27]. Conversations focus on reimbursement progress and commercial scale; downside concerns center on competition and execution [#SEC][#PR]. Overall narrative is watchful optimism with event-driven volatility likely.

RankAlpha Sentiment AI - 2025-10-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventQuarterly earnings releaseHigh impact

Regular quarterly results can drive short-term share moves via revenue guidance or margin commentary; market historically reacts to volume/coverage updates [#PRICE-2025-10-27].

-eventClinical data or commercial partnership announcementHigh impact

New peer-reviewed clinical results or strategic partnerships could boost adoption and conviction for growth; timing is uncertain [#PR].

-catalystReimbursement / payer coverage expansionHigh impact

Broader reimbursement for key genomic tests (Afirma/Percepta/Envisia) would materially increase addressable market and revenues over multiple quarters [#SEC].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-10-29 • Updated nightlySource: Internal modelMethodology